“Candy flipping” — mixing MDMA and LSD — is hitting the lab

Researchers have announced a phase 1 clinical trial of the popular drug combo.

“The co-administration of D-lysergic acid diethylamide (LSD; ‘Acid’) and 3,4-methylenedioxymethamphetamine (MDMA; ‘Ecstasy’; ‘XTC’) , has reached a prevalence that has allowed for the street terminology ‘candy flipping’ to describe the combination.”

All of which is an extremely square (and exceedingly late ’90s) way for the European Journal of Pharmacology to tell you that mixing LSD and MDMA is a pretty popular thing to do, and has been for decades.

But now, candy flipping is joining the psychedelic research renaissance and going from Drug World to the clinic to see if the hedonists may have found some therapeutic insights.

Some psychedelic researchers think the combo may have therapeutic benefits greater than the sum of its parts — others think its benefits are dubious and risks potentially dangerous.

The Experiment

Psychedelic pharmaceutical company MindMed and the Liechti Lab at the University of Basel (that’s in Switzerland) have announced a phase 1 clinical trial, the first of its kind, studying candy flipping’s effects.

A cohort of 24 healthy subjects will be dosed over four different sessions. They’ll receive either 100 milligrams of MDMA with an LSD placebo; 100 micrograms of LSD with an MDMA placebo; both placebos; or both drugs. 

The researchers will take empirical measurements — blood pressure, body temperature, heart rate — as well as reporting the patients’ subjective feelings about each combo. 

The objective is to figure out if MDMA’s well-known capacity for engendering the warm fuzzies can help take the edge off of an LSD trip. If so, it may make LSD-enhanced therapy a more palatable option for more potential patients.

“The potential of MDMA-LSD is to create a psychological state that may have the benefits of both substances and have longer lasting effects than standalone psilocybin or LSD,” Matthias Liechti, the lab’s namesake, said in a press release.

…Is This a Good Idea?

One may not be able to just cherry pick the best of both drug’s psychedelic effects, however.

“It’s not as simple as combining the euphoria (and) anti-anxiety effects of MDMA with the interoprospective psychedelic effects of LSD,” Charles Nichols, a professor of pharmacology at LSU (and second-generation psychedelic researcher), wrote in an email.

MDMA dumps a lot of serotonin and dopamine into the brain, and those high levels will activate the two brain chemical’s receptors, desensitizing them to a degree, Nichols says. Combined with LSD activating multiple dopamine and serotonin receptors, candy flipping could lead to serotonin syndrome, which can cause anything from shivers to seizures.  

“Going straight into humans without an understanding of how these two drugs interact at the physiological and metabolic level is potentially dangerous, and risky at best,” Nichols wrote. 

“This type of interaction really hasn’t been studied at a rigorous biological level, let alone what the behavioral consequences would be. Relying on raver reports on candy flipping as a justification for safety in humans for a clinical trial is bad science and downright dangerous.”

So, you’ve been warned.

Candy flipping’s clinical debut is scheduled to begin in late 2020, and the trial hasn’t yet begun to recruit, meaning there’s still time for aspiring psychonauts to hit Spotify for the perfect playlist and hydrate (for science, of course).

Editor’s note: This story was edited on 9/23/20 to correct the dosage of the study design; participants may receive 100 milligrams of MDMA, not micrograms.

Psychedelic drugs and the law: What’s next?
The push to legalize magic mushrooms, MDMA, LSD, and other hallucinogens is likely to heighten tensions between state and federal law.
Does caffeine harm your decision-making?
A small study showed caffeine lessens decision-making. While preliminary, it raises questions about caffeine affects our “higher” cognitive functions.
Professor Giles Yeo on making sense of anti-obesity drugs
Anti-obesity drugs have been in the news, and for good reason; they seem to work. Giles Yeo talks us through some misconceptions at play.
A new hydrogel offers the hope of ending daily injections for diabetes
Type-2 diabetes often involves an intense and exhausting treatment burden, with many injections over many days. That might be set to change.
Australia’s 30-year quest to unlock an ancient painkiller
A crocodile attack led to a 30-year partnership to develop a painkiller based on the Nyikina Mangala people’s traditional knowledge.
Up Next
microdosing lsd
Subscribe to Freethink for more great stories